Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. SQZ Biotechnologies Co's Total Liabilities for the quarter that ended in Sep. 2023 was $27.91 Mil. SQZ Biotechnologies Co's Total Assets for the quarter that ended in Sep. 2023 was $29.79 Mil.
Therefore, SQZ Biotechnologies Co's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2023 was 0.94.
SQZ Biotechnologies Co (OTCPK:SQZB) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
SQZ Biotechnologies Co Liabilities-to-Assets Related Terms
SQZ Biotechnologies Co Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for SQZ Biotechnologies Co's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SQZ Biotechnologies Co Liabilities-to-Assets Chart
SQZB vs AGTX, ISCO, VYNT: Liabilities-to-Assets Comparison
For the Biotechnology subindustry, SQZ Biotechnologies Co's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SQZ Biotechnologies Co Liabilities-to-Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SQZ Biotechnologies Co's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where SQZ Biotechnologies Co's Liabilities-to-Assets falls into.
SQZ Biotechnologies Co Liabilities-to-Assets Calculation
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
SQZ Biotechnologies Co's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2022 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SQZ Biotechnologies Co (SQZB) has a Liabilities-to-Assets of 0.94 as of Sep. 2023. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on SQZ Biotechnologies Co and its competitors.
Is SQZ Biotechnologies Co's Liabilities-to-Assets too high?
SQZ Biotechnologies Co's current Liabilities-to-Assets is 0.94. Overall, SQZ Biotechnologies Co has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SQZ Biotechnologies Co's Liabilities-to-Assets compare to AGTX and ISCO?
SQZ Biotechnologies Co's Liabilities-to-Assets of 0.94 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on SQZ Biotechnologies Co and its competitors. SQZ Biotechnologies Co's current Liabilities-to-Assets is 0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SQZ Biotechnologies Co stock overvalued right now?
SQZ Biotechnologies Co (SQZB) has a current Liabilities-to-Assets of 0.94. The current Liabilities-to-Assets is 0.94. SQZ Biotechnologies Co's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For SQZ Biotechnologies Co (SQZB), the current Liabilities-to-Assets is 0.94 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SQZ Biotechnologies Co is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the ability to deliver multiple materials into many patient cell types to engineer what it believes to be an unprecedented range of potential therapeutics for a range of diseases. The company has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and potentially improve the patient experience over existing cell therapy approaches, with accelerated production timelines under 24 hours and the elimination of preconditioning and lengthy hospital stays.
12GF Score
Get the complete analysis for SQZB
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SQZB has been successfully added to your 
